Growth Hormone-Releasing Hormone Agonist Protects Eye Nerve Cells After Injury
The GHRH agonist MR-409 promoted retinal ganglion cell survival after optic nerve injury in rats and enhanced the protective effects of macrophage activation, suggesting therapeutic potential for glaucoma.
Quick Facts
What This Study Found
GHRH agonist MR-409 protected retinal ganglion cells after optic nerve injury and additively enhanced macrophage-mediated neuroprotection, with effects mediated through Akt phosphorylation and microglial activation.
Key Numbers
GHRH-R on RGCs confirmed; MR-409 increased RGC survival; Akt phosphorylation increased; microglia activated by agonist; IL-1β, IL-6, TNF reduced by antagonist
How They Did This
Rat optic nerve crush model. Subcutaneous GHRH agonist (MR-409) or antagonist (MIA-602) treatment. RGC survival quantification, retinal Akt phosphorylation, microglial activation, inflammation gene expression, and combination with lens injury/zymosan-induced macrophage activation.
Why This Research Matters
Glaucoma affects over 100 million people worldwide with no cure. Finding that GHRH agonists can protect retinal nerve cells and enhance existing neuroprotective mechanisms opens a new therapeutic avenue for preserving vision.
The Bigger Picture
Current glaucoma treatments focus on lowering eye pressure, but nerve cell damage often continues. GHRH agonists represent a fundamentally different approach — directly protecting the nerve cells themselves — which could complement pressure-lowering treatments for better outcomes.
What This Study Doesn't Tell Us
Rat model — optic nerve crush differs from the gradual nerve damage in human glaucoma. Subcutaneous administration raises questions about achieving sufficient drug levels in the eye. Long-term effects not studied.
Questions This Raises
- ?Could GHRH agonists be delivered directly to the eye for greater effect?
- ?Would GHRH agonists work in chronic glaucoma models with gradual nerve damage?
- ?Are there systemic side effects of GHRH agonists that would limit their use for eye disease?
Trust & Context
- Key Stat:
- Additive neuroprotection GHRH agonist MR-409 enhanced macrophage-mediated RGC survival beyond either treatment alone
- Evidence Grade:
- Published in PNAS with thorough mechanistic investigation. High-quality preclinical evidence from a well-designed animal study.
- Study Age:
- Published in 2021, revealing a novel application for GHRH agonists in optic neuropathy.
- Original Title:
- Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury.
- Published In:
- Proceedings of the National Academy of Sciences of the United States of America, 118(28) (2021)
- Authors:
- Cen, Ling-Ping, Ng, Tsz Kin(2), Liang, Jia-Jian, Xu, Ciyan, Zhuang, Xi, Liu, Yu-Fen, Chen, Shao-Lang, Xu, Yanxuan, Yang, Qichen, Yuan, Xiang-Ling, Qin, Yong Jie, Chan, Sun On, Chen, Haoyu, Zhang, Mingzhi, Schally, Andrew V, Pang, Chi Pui
- Database ID:
- RPEP-05305
Evidence Hierarchy
Frequently Asked Questions
Could this peptide help people with glaucoma?
Potentially. This study shows that a GHRH agonist (MR-409) protects retinal nerve cells after optic nerve injury in rats and enhances other protective mechanisms. If these results translate to humans, it could complement current glaucoma treatments that only lower eye pressure.
What's the difference between the GHRH agonist and antagonist effects?
Both protected nerve cells, but through different mechanisms. The agonist (MR-409) activated immune cells in the retina and enhanced inflammation-driven protection, while the antagonist (MIA-602) reduced inflammatory gene expression. Only the agonist showed additive benefits when combined with other protective treatments.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05305APA
Cen, Ling-Ping; Ng, Tsz Kin; Liang, Jia-Jian; Xu, Ciyan; Zhuang, Xi; Liu, Yu-Fen; Chen, Shao-Lang; Xu, Yanxuan; Yang, Qichen; Yuan, Xiang-Ling; Qin, Yong Jie; Chan, Sun On; Chen, Haoyu; Zhang, Mingzhi; Schally, Andrew V; Pang, Chi Pui. (2021). Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury.. Proceedings of the National Academy of Sciences of the United States of America, 118(28). https://doi.org/10.1073/pnas.1920834118
MLA
Cen, Ling-Ping, et al. "Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury.." Proceedings of the National Academy of Sciences of the United States of America, 2021. https://doi.org/10.1073/pnas.1920834118
RethinkPeptides
RethinkPeptides Research Database. "Agonist of growth hormone-releasing hormone enhances retinal..." RPEP-05305. Retrieved from https://rethinkpeptides.com/research/cen-2021-agonist-of-growth-hormonereleasing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.